Dasatinib is a kinase inhibitor used to treat certain types of leukemia in both adults and children 1 year of age and older, including cases where previous treatment were not effective or tolerated.

The payouts from Heritage and Apotex follow a series of other price-fixing settlements inked this year. Most recently, Glenmark Pharmaceuticals in early September agreed to pay the Justice ...

LANSING, Mich. (WLNS) — If you purchased a generic prescription drug manufactured by Heritage Pharmaceuticals or Apotex between 2010 and 2018, you may be eligible for compensation. 50 states and ...

Two of them, Apotex and Heritage Pharmaceuticals, agreed to a settlement that awards money to consumers who purchased certain Apotex and Heritage products during the nine-year span. As part of ...

Oct 31 (Reuters) - Generic drugmakers Apotex and Heritage Pharmaceuticals have agreed to pay nearly $50 million to settle claims by Connecticut and other states that accused them of conspiring to ...

In the ongoing litigation over Apotex's generic version of GlaxoSmithKline's (GSK) antidepressant paroxetine hydrochloride (Paxil), the US Federal Circuit Appeals Court has reversed the previous ...

Delaware was one of 50 states and territories to reach cooperation agreements and settlements with Heritage Pharmaceuticals and Apotex for their reported efforts to manipulate prices, reduce ...

BALTIMORE, MD (WBFF) — Attorney General Anthony G. Brown reached two significant settlements with Heritage Pharmaceuticals and Apotex totaling $49.1 million. The companies are being accused of ...

Attorney General Phil Weiser announced the $10 million settlement with Heritage Pharmaceuticals and $39.1 million settlement with Apotex on Thursday. Colorado joined three multistate lawsuits ...

Canadian generic drug manufacturer Apotex Inc. is making plans for a potential initial public offering next year, according to people familiar with the matter. We apologize, but this video has failed ...

The Heart Outcomes Prevention Evaluation (HOPE) study was a landmark study employing the angiotensin-converting enzyme (ACE) inhibitor ramipril in a patient population predestined for vascular events.

Ramipril ist ein Arzneistoff der Gruppe der ACE-Hemmer, der zur Behandlung der arteriellen Hypertonie (Bluthochdruck) und der Herzinsuffizienz und zur Vorbeugung des Herzinfarktes eingesetzt wird.